BAN2401 Slows Cognitive Decline in Alzheimer Disease
BAN2401 produced a dose-dependent substantial reduction in brain amyloid plaque at the highest dose, resulting in subjects converting to amyloid negative.
FDA Expands Parkinson, Tremor DBS Therapy With Magnetic Resonance-Conditional Labeling
Abbott’s Infinity Deep Brain Stimulator now allows for performance of MRI on patients with Parkinson or essential tremor with the system implanted.
John Walsh, MD, on the FDA Acceptance of NDA for Cladribine Tablets for MS
The vice president of US Medical Affairs in Neurology & Immunology at EMD Serono discussed the potential for the oral multiple sclerosis therapy.
Fingolimod Shows Higher Retention Than Injectable DMTs Among African-American Patients with MS
African-American patients with MS on fingolimod were 50.2% more likely to remain true to their treatment regimen than those treated with injectable disease-modifying therapies.
FDA Accepts NDA for Cladribine Tablets for MS Treatment
The EMD Serono therapy’s resubmission was accepted after a 2011 CRL, with the new NDA supported by the findings of a 5-study clinical development program.
FDA Places DMD Gene Therapy Trial on Hold
A third-party manufacturing issue has delayed a phase I/IIa study for Sarepta Therapeutics.
Lynn Kramer, MD: BAN2401 Phase IIb Clinical Study Results
This is the first large late-stage clinical trial to further support the amyloid hypothesis.
Jeff D. Williamson, MD, MHS: SPRINT-MIND Trial Preliminary Results
The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.
Krista Lanctot, PhD: Nabilone Significantly Improves Agitation in Alzheimer Disease
The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.
Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis
Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.
Alzheimer's Association Develops First Practice Guidelines for Clinical Evaluation of Alzheimer Disease, Other Dementias
The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
James Hendrix, PhD: First Practice Guidelines for Clinical Evaluation of Alzheimer Disease Released
These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.
FDA Grants Alzheimer Biomarker Test Breakthrough Status
The FDA has granted a Breakthrough Device Designation to the Elecsys beta-Amyloid (1-42) and Elecsys Phospho-Tau (181P) cerebrospinal fluid assays, which can be used in the diagnosis of Alzheimer disease.
Neural Insights on Social Exclusion
Neurological findings tell us why decision-making functions of the brain can be altered based on certain life experiences.
Investigational Therapy TNX-102 SL Receives FDA Fast Track for Agitation in Alzheimer Disease
TNX-102 SL’s impact on sleep disturbance highlights a mechanism of action that could result in positive effects on agitation in AD.
ZX008 Significantly Reduces Seizures in Dravet Syndrome
The addition of ZX008 to background stiripentol significantly reduced the number of convulsive seizures experienced by children and young adults with Dravet syndrome.
CGRP Infusion Shows Efficacy in Cluster Headache Management
After success in migraine treatment, CGRP has now shown a positive effect on acute cluster headache in a randomized clinical trial.
FDA Accepts Sodium Oxybate Application for Children With Narcolepsy
The FDA has accepted a supplemental new drug application for sodium oxybate as a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy.
Can Neurologists Identify Patient Suicide Warnings?
Given that suicide is increasing as a public health concern, better identification of warning signs could assist in directing preventative strategies to the right people.
Positive Topline Results Announced for BAN2401 in Phase II Alzheimer Trial
The anti-amyloid protofibril antibody achieved statistical significance in its key efficacy endpoints after 18 months.
Sports and Headaches: A Risky Business Quiz
Which sports-related migraine is associated with longer recovery time, as well as cognitive, neurobehavioral, and somatic symptoms? Test your skills in this quiz.
Promising Cell Therapy Unavailable for ALS Under Right-to-Try
The autologous stem cell therapy is currently in a phase III trial.
Galcanezumab Shows Efficacy in Cluster Headache, Migraine
Phase III results have shown galcanezumab is efficacious for multiple headache conditions.
Eptinezumab Reduces Monthly Migraine Days Post-Third, Fourth Infusions
The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.
Rimegepant Eases Pain, Resolves Symptoms for Acute Migraine
Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.
Quarterly Infusions of Eptinezumab Highly Effective for Migraine Prevention in PROMISE 2
The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.
Neurology Comic: Stress Test
We're trying to make our stress tests more realistic.
Riluzole Prolongs Late-Stage Survival in ALS
A retrospective analysis of a dose-ranging trial found that those who were administered 100-mg daily riluzole, in comparison with placebo, spend a longer period of time in stage 4 of ALS.
FDA Accepts APL-130277 Application for OFF Episodes in PD
The FDA had accepted a new drug application for APL-130277, a sublingual film version of apomorphine, as a treatment for OFF episodes in patients with Parkinson disease.
